Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.51 |
| ▸ | PARL | Q9H300 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16912986 | 0.89 | SMN1; SMN2 (0.64) | SMN1; SMN2HTTRECQLALDH1A1LMNA | |
| SCHEMBL1519692 | 0.85 | ALDH1A1 (0.69) | SMN1; SMN2HTTRECQLALDH1A1LMNA | |
| SCHEMBL16912996 | 0.84 | EPHX2 (0.63) | SMN1; SMN2HTTRECQLALDH1A1LMNA | |
| SCHEMBL854322 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTRECQLALDH1A1LMNA | |
| SCHEMBL30005295 | 0.84 | SMN1; SMN2 (0.63) | SMN1; SMN2HTTRECQLALDH1A1LMNA | |
| SCHEMBL23271159 | 0.84 | LMNA (0.72) | SMN1; SMN2HTTALDH1A1LMNAEPHX2 | |
| SCHEMBL7130169 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTRECQLALDH1A1LMNA | |
| SCHEMBL7133340 | 0.82 | SMN1; SMN2 (0.60) | SMN1; SMN2HTTRECQLALDH1A1LMNA | |
| SCHEMBL21681941 | 0.82 | ALDH1A1 (0.74) | SMN1; SMN2HTTRECQLALDH1A1LMNA | |
| SCHEMBL7485956 | 0.82 | ALDH1A1 (0.79) | SMN1; SMN2HTTRECQLALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889716-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889716-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889716-B2 | Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2012-11-29 | — | — | US | disclosed |
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2012-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120302539-A1 | TRANSGLUTAMINASE TG2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HTT, TGM2, GRN | SMN1; SMN2 216/4885HTT 1/4885RECQL 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.